Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Implant or insert

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424423000 Surgical implant or material 1128
424427000 Ocular 146
424430000 Vaginal, urethral, uterine 67
424434000 Mucosal (e.g., nasal, etc.) 31
424437000 Otic 3
20090017098COMPOSITION AND METHOD FOR THE PREVENTION AND RELIEF OF THE SYMPTOMS OF AN INCOMPETENT OR PATULOUS EUSTACHIAN TUBE - A composition and methods for the treatment of symptoms due to disorders, disease or trauma that impairs normal function of die Eustachian tube and alters vital structures or tissues of the middle ear. This includes diseases and disorders of the Eustachian tube altered by tubal incompetence, inflammatory phenomenon as rhinitis, nasal allergies, infections by microorganisms, tympanic membrane rupture or trauma and variants. The composition is comprised of solution including L-Ascorbic acid and a pharmaceutically acceptable liquid carrier and delivery system. The administration of which is applied topically in appropriate composition and dosage for intranasal or trans tympanic route in the form of drops, spray, aerosol, rinse, douche, gel, or devices.01-15-2009
20090246255Pharmaceutical Compositions for the Treatment of Inner Ear Disorders - The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine or a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. These compositions or medicaments containing these compositions may be used for the prevention and/or treatment of inner ear diseases, e.g. tinnitus.10-01-2009
20090317448TYMPANIC MEMBRANE PATCH - The invention features methods of making living tissue constructs that can be used to repair perforations in tympanic membranes, the repair constructs themselves, and methods of repair.12-24-2009
Entries
DocumentTitleDate
20090017087Osseoinductive metal implants for a living body and producing method thereof - This invention provides an Osseo-inductive metal implant for a living body and the producing method thereof and, more particularly, the Osseo-inductive metal implant for a living body according to the present invention is produced by forming, on the surface of the metal implant, the layer of metal oxide and the layer of bio-active material injected.01-15-2009
20090123511BIOMATERIAL DERIVED FROM VERTEBRATE LIVER TISSUE - A tissue graft composition comprising liver basement membrane is described. The graft composition can be implanted to replace or induce the repair of damaged or diseased tissues.05-14-2009
20090123510Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening - The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A05-14-2009
20090123508Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management - The present disclosure provides an intrathecally-implantable depot having a biodegradable core for extended release of pain-relieving drug into the intrathecal space over at time period of at least a month. The present disclosure further provides methods for preparing a self-contained intrathecally-implantable depot and methods for continuously relieving pain in a subject by implanting an intrathecally-implantable depot having a biodegradable core and releasing a therapeutically-effective amount of analgesic composition from the biodegrading core over a time period of at least one month.05-14-2009
20090196898STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED - Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process.08-06-2009
20100021516DRUG DEPOTS HAVING ONE OR MORE ANCHORING MEMBERS - A drug depot implantable at or near a target tissue site beneath the skin of a patient is provided, the drug depot comprising a therapeutically effective amount of a drug and at least one surface adapted to receive one or more anchoring members so as to limit movement of the drug depot at or near the target tissue site, wherein at least one region of the drug depot is capable of releasing the therapeutically effective amount of the drug over a period of at least one day. In some embodiments, the drug depot provided can include an effective amount of at least analgesic and at least one anti-inflammatory agent at or near a target site, and can reduce, prevent or treat inflammation and/or pain, particularly postoperative pain.01-28-2010
20090028918Gynecological pharmaceutics- containing microspherical vascular suppository of sodium alginate and its preparation method - The present invention relates to a kind of sodium alginate microsphere vascular embolus containing gynecological drug and its preparation. The preparation of it consists of the following steps: preparing the solution of gynecological drug, sodium alginate and dilvalent metal cations such as BaCl01-29-2009
20100008966Medical Devices and Methods for Delivery of Nucleic Acids - Embodiments of the invention include devices for the release of nucleic acids and related methods. In an embodiment, the invention includes an active agent eluting coating including a polymeric matrix, a cationic carrier agent disposed with the matrix, and an active agent disposed within the matrix, the active agent including nucleic acids substantially uncomplexed with the cationic carrier agent. In an embodiment, the invention includes a method of making an implantable medical device including selecting a concentration of a cationic carrier agent corresponding to a desired elution profile, combining a matrix forming polymer, an active agent, a solvent, and the cationic carrier agent to form a coating composition having the selected concentration of the cationic carrier agent, the active agent comprising nucleic acids, and depositing the coating composition onto the surface of a substrate. Other embodiments are included herein.01-14-2010
20100080837COMPOSITIONS AND METHODS FOR REDUCING THE LIKELIHOOD OF IMPLANTATION FAILURE OR SPONTANEOUS ABORTION IN RECIPIENTS OF ASSISTED REPRODUCTION - Methods and kits for preventing or reducing the likelihood of implantation failure or spontaneous abortion in a recipient of FET, ICSI, GIFT or ZIFT are provided. The methods include administering into a recipient of FET, ICSI, GIFT or ZIFT in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).04-01-2010
20100158969FLEXIBLE IMPLANTABLE COMPOSITES AND IMPLANTS COMPRISING SAME - Described herein are implantable composites, kits comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.06-24-2010
20100119572POLYVINYL ALCOHOL MICROSPHERES, INJECTABLE SOLUTIONS AND THERAPEUTIC USES OF THE SAME - The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres.05-13-2010
20100119569SYSTEMS FOR IMPROVING MATERIAL EXCHANGE WITH AN IMPLANT - A system for implanting a device within a biological target region for exchange of material with the biological target region is provided. The system includes an implantable device and a plurality of precursor cells. The implantable device has at least one recess on a first surface of the device, and a filter configured to allow communication between the at least one recess and an internal portion of the device. The at least one recess is configured to receive the precursor cells and to allow the cells to mature and convert into microvessels disposed along the recesses.05-13-2010
20100074935RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.03-25-2010
20100074934MEDICAL IMPLANTS WITH A COMBINATION OF COMPOUNDS - Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and peripheral vascular stents, catheters, balloons), non-vascular stents, pumps and sensors, vascular grafts, perivascular devices, implants for hemodialysis access, vena cava filters, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and fillers.03-25-2010
20100074933Cell And Enzyme Compositions For Modulating Bile Acids, Cholesterol and Triglycerides - The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier.03-25-2010
20090004237B7-Like Molecules and Uses Thereof - The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.01-01-2009
20100034859Method for making an implantable biocompatible material with mixed Pseudo-crystalline lattice and material obtainable by said method - The invention concerns a method for making a biocompatible material implantable in a human or animal body including: a step (a) of dispersing at least one biocompatible substance in a solvent, to obtain an intermediate solution; a step (b) of condensation of said intermediate solution to obtain an amorphous condensate of said biocompatible substance; a step (c) of mixing the biocompatible substance with at least one agent for nucleating said biocompatible substance; a step (d) of activating the nucleating agent to generate the development, within said amorphous condensate, a mixed pseudo-crystalline lattice consisting of both the biocompatible substance and the nucleating agent, so as to obtain a biocompatible material at least partly crystallized. The invention also concerns biocompatible materials implantable in a human or animal body.02-11-2010
20080254087Methods For Administering Hypoglycemic Agents - The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists.10-16-2008
20080268010N-ALKYLATED RIFAMPIN - Compounds of the formula:10-30-2008
20100098735INJECTABLE DEPOT COMPOSITIONS AND ITS PROCESS OF PREPARATION - Novel injectable compositions are provided comprising an active agent which is tamsulosin or letrozole or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof and one or more pharmaceutically acceptable excipient(s) wherein the compositions are preferably formulated as biodegradable microparticles or nanoparticles which can optionally be reconstituted with an aqueous, hydro-alcoholic or oily liquid vehicle prior to administration. The novel injectable compositions of the present invention preferably form a depot upon administration in vivo and are in the form of an in situ gelling composition or an implant composition which provides a prolonged release of tamsulosin or letrozole for extended periods of time. Also described are process for preparation of such novel compositions and method of using them.04-22-2010
20130101656IN SITU GELLING DRUG DELIVERY SYSTEM - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.04-25-2013
20090155331INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.06-18-2009
20130045266METHOD FOR PREPARING POLYMERIC BIOMATERIALS HAVING IMMOBILIZED DRUG DELIVERY SYSTEM COMPRISING BIOACTIVE MOLECULES LOADED PARTICLE CARRIER - A new polymeric material for biological tissue regeneration or treatment with a drug delivery system which contains therapeutic agents and/or bioactive molecules to reduce infection and inflammatory reaction at a wound site and maximize tissue regeneration and wound healing is provided. The new bioactive molecule-loaded polymeric material is prepared by (1) preparing micrometer or nanometer sized bioactive molecule-loaded particles; (2) modifying the surface of the prepared particles and immobilizing the particles on the surface of the polymeric material; and (3) physically treating the surface of the polymeric material to improve binding strength of the particles immobilized thereon.02-21-2013
20120164207Degradable networks for sustained release and controlled release depot drug delivery applications - Provided herein is a controlled release and/or sustained release depot drug delivery system, comprising, a biodegradable polymer coating and an API coated with the biodegradable polymer coating, wherein a quantity of API coated with biodegradable polymer is effective to be released from the biodegradable polymer coating over a prolonged period of time.06-28-2012
20090317437CELLULOSE GEL FORMULATIONS - The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed cellulose powder compositions.12-24-2009
20080274155Chimeric Cannulae Proteins, Nucleic Acids Encoding Them And Methods For Making And Using Them - The invention provides chimeric cannulae polypeptides and nanotubules and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one aspect, the invention provides compositions and methods for the selection and purification of chiral compositions from racemic mixtures. In one aspect, the chimeric proteins and polymers (e.g., nanotubules, tubules, bundles, balls, fibers, filaments, sheets, threads, textiles) of the invention comprise a detectable moiety, e.g., a fluorescent protein. In one aspect, the invention provides a flame retardant or heat resistant device comprising a sheeting, a covering, a coating or an adhesive comprising a chimeric protein of the invention.11-06-2008
20090041822TISSUE TRANSPLANT CONSTRUCT FOR THE RECONSTRUCTION OF A HUMAN OR ANIMAL ORGAN - The invention relates to a tissue transplant construct for the reconstruction of a human or animal organ, where the tissue transplant construct comprises: 02-12-2009
20100272772APPARATUS, SYSTEM, AND METHOD FOR CREATING IMMUNOLOGICALLY ENHANCED SPACES IN-VIVO - The present invention creates an immunologically protected/enhanced space in viva in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within the body. Placing an antigen source within the defined protected space along with a monocyte-containing blood sample from the mammal being treated and a dendritic cell-inducing factor allows a dendritic-antigen presentation process to proceed to completion. The protected/enhanced space is created by surrounding the protected space with ligands which absorb and/or bind to one or more soluble inhibitors. The implant can be loaded with a patient's cancer cells to treat cancer.10-28-2010
20130071462Drug Delivery Systems and Applications - Certain embodiments of the invention include medical materials and methods comprising a biodegradable hydrophilic hydrogel comprising dispersed lipophilic particles that comprise a therapeutic agent, wherein the lipophilic particles have a low water solubility in physiological saline at physiological temperature.03-21-2013
20090092651ABSORBABLE ADHESIVES AND THEIR FORMULATION FOR USE IN MEDICAL APPLICATIONS - Described are medical products including an adhesive containing a polypeptide component such as gelatin and a tackiness-providing polyhydroxy compound, such as at least one compound selected from the group consisting of glycerin and fructose. Such medical products can find use as a bolster material for use in conjunction with a surgical fastening device such as a stapler. Other medical applications utilizing a medical product of the invention include tissue repair and pharmaceutical delivery to a desired location. Related methods of manufacture and use are also described.04-09-2009
20110059147LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 03-10-2011
20110014260SYSTEM AND METHOD FOR LIVER CELL CULTURE AND MATURATION - The present invention relates to systems and methods for maturation, proliferation and maintenance of function in cells presenting hepatocyte characteristics and differentiated from stem cells. The cells of the present invention may be generated from stem cell grown in collagen sandwich configuration in the presence of a morphogen (e.g. S-NitrosoAcetylPenicillamine (SNAP) or Oncostatin-M (OSM)).01-20-2011
20090269383MEDICAL DEVICES HAVING INORGANIC PARTICLE LAYERS - An expandable medical device having a particle layer disposed over a reservoir containing a therapeutic agent. The particle layer has a first porosity when the medical device is in the unexpanded configuration and a second porosity when the medical device is in the expanded configuration. The particle layer comprises a plurality of micron-sized or nano-sized particles. In certain embodiments, the particles are not connected to each other, and as such, the different porosities are provided by changes in the spacing between the particles as the medical device is expanded/unexpanded. Also disclosed are medical devices having a particle layer, wherein the particle layer comprises a plurality of encapsulated particles, and methods of coating medical devices with particles.10-29-2009
20090232865End-Capped Poly(Ester Amide) Copolymers - This invention relates to poly(ester amide)s (PEAs) comprising inactivated terminal amino and carboxyl groups, methods of synthesizing the inactivated PEAs and uses for them in the treatment of vascular diseases.09-17-2009
20090232864METHOD FOR APPLYING A BIOACTIVE, TISSUE-COMPATIBLE LAYER ONTO SHAPED ARTICLES AND THE USE OF SUCH SHAPED ARTICLES - A method for applying a bioactive, tissue-compatible layer onto a shaped article includes providing, as a target material, a bioactive glass ceramic having a S53P4 composition, cleaning a shaped article and activating a surface of the shaped article with ions. The Shaped article is exposed to a bioactive glass ceramic beam pulse ablated by a pulsed electron-beam ablation of the bioactive glass ceramic target material so as to deposit a bioactive glass ceramic layer having a thickness ranging from 1 μm to 10 μm on the surface of the shaped article. A respective pulse frequency of the at least one of: 1) an electron pulse of the pulse electron beam abalation, and 2) the bioactive glass ceramic beam pulse, is controlled. Prior to an implantation, so as to avoid an initial cytotoxicity, at least one of the following is performed: a) an exposure of the article at least the times to 09-17-2009
20090232863Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers - Disclosed herein are implantable medical devices coated with or comprising bioabsorbable carbon-based nitric oxide-donating polymers that upon exposure to physiological environments donate nitric oxide (NO).09-17-2009
20090047318NANOPARTICLE-COATED MEDICAL DEVICES AND FORMULATIONS FOR TREATING VASCULAR DISEASE - Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed.02-19-2009
20090010985Article with Lubricated Surface and Method - Articles having reduced sliding frictional force comprising a lubricant applied to one or more surfaces of the article, and the lubricant-coated surface treated by exposing the surface to an energy source, wherein the energy source is an ionizing gas plasma at about atmospheric pressure. The ionizing gas plasma may be a flame plasma. One or more of the surfaces may be exposed to the ionizing gas plasma at about atmospheric pressure prior to application of the lubricant.01-08-2009
20090010984STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE BIOMATERIAL, THE PREPARATION AND USES THEREOF - A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial.01-08-2009
20090010983Alginate Coated, Polysaccharide Gel-Containing Foam Composite, Preparative Methods, and Uses Thereof - The invention relates to composites comprising a polysaccharide gelled within pores of a foam and an polysaccharide coating, methods of preparation, and uses thereof, for example, in biomedical applications such as cell culture media and implants, controlled release delivery systems, food applications, industrial applications, and personal care applications such as cosmetic and oral hygiene.01-08-2009
20090010982BIOCOMPATIBLE ADHERENT SHEET FOR TISSUE SEALING - A biocompatible adherent sheet for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The biocompatible adherent sheet includes a carrier sheet including a biocompatible polymer and a modified chitosan evenly disposed on one or both sides of the carrier sheet. Methods of preparing a biocompatible adherent sheet and methods of using a biocompatible adherent sheet are also provided. The biocompatible adherent sheet may also include a bioactive agent.01-08-2009
20090010986Polymeric gel delivery system for pharmaceuticals - Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.01-08-2009
20090317438WHOLE BLOOD-DERIVED COAGULUM DEVICE FOR TREATING BONE DEFECTS - Whole blood-derived coagulum devices are described for use in treating bone defects.12-24-2009
20090098175METHODS AND COMPOSITIONS FOR DELIVERY OF GROWTH FACTOR TO FIBROUS CONNECTIVE TISSUE - The presently disclosed subject matter relates to a peptide composition for non-covalently localizing fibrous connective tissue-inducing growth factor to a surface of an implant, the composition comprising a peptide having binding affinity for a surface material of an implant coupled to a peptide having binding affinity for a fibrous connective tissue-inducing growth factor. Methods are provided for delivering fibrous connective tissue-inducing growth factor GDF-7 in an amount effective to promote fibrous connective tissue repair and fibrous connective tissue formation. Also provided are methods of applying the peptide composition to an implant by contacting the composition with a surface of the implant; and kits comprising the compositions.04-16-2009
20100189759CHEMICAL TREATMENT FOR REMOVING CELLULAR AND NUCLEAR MATERIAL FROM NATURALLY OCCURRING EXTRACELLULAR MATRIX-BASED BIOMATERIALS - A method is provided for sequential decellularization of an isolated tissue using solubilizing solutions comprising at least one oxidizing agent that removes all cellular and nuclear materials from the tissue while substantially maintaining the biological and, mechanical properties, and the biochemical properties of the resulting extracellular matrix.07-29-2010
20100008964ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells.01-14-2010
20110014259ALPHA ADRENERGIC RECEPTOR AGONISTS FOR PREVENTION OR TREATMENT OF A HEMATOMA, EDEMA, AND/OR DEEP VEIN THROMBOSIS - Effective treatments of hematomas, edema, or other fluid accumulation or deep vein thromboses are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat edema, or other fluid accumulation or deep vein thromboses.01-20-2011
20100322991HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.12-23-2010
20110033516METHODS AND COMPOSITIONS FOR BONE HEALING BY PERIOSTIN - The present invention provides methods and compositions for increasing bone production and/or decreasing bone fracture healing time in a subject, by administering an effective amount of periostin and/or active peptides and/or fragments thereof.02-10-2011
20090162411ENCAPSULATED KIDNEY TISSUE - Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated.06-25-2009
20110086079Methods for Producing Hair Microfollicles and De Novo Papillae and Their Use for In Vitro Tests and In Vivo Implantations - The present invention relates to a method for producing hair microfollicles comprising the steps of: a) providing de novopapillae, b) providing other cell populations selected from the group of fibroblasts, keratinocytes and melanocytes, and co-culturing the de novopapillae with at least one other cell population in non-adherent culture vessels. The present invention relates also to methods of producing de novo papillae usable in said method for producing hair microfollicles.04-14-2011
20100272771Device including bone cage and method for treatment of disease in a subject - Devices, methods, and systems are described for controlling pathogenic condition or disease in a subject. Devices are described that include one or more bone cages. The device including one or more bone cages can be configured to include one or more immunogens and one or more adjuvants. The device including one or more bone cages can be configured to, and/or structured to at least partially or completely surround one or more cells or tissues that produce one or more immunogens and/or one or more adjuvants. The device is useful in a method for treating a pathogenic condition or disease in the subject.10-28-2010
20110287078NOVEL POROUS BIOMATERIALS - The invention provides porous biomaterials and methods for forming porous biomaterials. The porous biomaterials of the invention comprise a biocompatible polymer scaffold defining an array of pores, wherein substantially all the pores have a similar diameter, wherein the mean diameter of the pores is between about 20 and about 90 micrometers, wherein substantially all the pores are each connected to at least 4 other pores, and wherein the diameter of substantially all the connections between the pores is between about 15% and about 40% of the mean diameter of the pores. The invention also provides implantable devices comprising a layer of a biomaterial, and methods for promoting angiogenesis in and around an implantable biomaterial.11-24-2011
20090148487MOLDABLE BIOMATERIAL FOR BONE REGENERATION - The present invention is directed to a moldable biomaterial comprising a particulate solid porous material and a biodegradable paste material. The paste material and the particulate solid porous material form a matrix usable for the replacement or augmentation of bone. In various embodiments the matrix has a high structural integrity, which does not immediately or shortly after implantation collapse into an amorphous non-porous mass, maintains its porosity after implantation, shows biphasic degradation after implantation and/or has a good resistance against being washed out when it is applied to a wet opened implant site. Active agents can be incorporated in the moldable biomaterial of the present invention, such as bone growth factors. Kits, implants, method of manufacturing as well as medicinal uses are also provided.06-11-2009
20110293684SURFACE-COATED STRUCTURES AND METHODS - The present invention relates to a methods and composition in which a D-form or retro-inverso 12-01-2011
20110293685SCAFFOLDS FOR TISSUE ENGINEERING AND REGENERATIVE MEDICINE - The methods and compositions described herein relate to novel 3-dimensional porous scaffolds useful for tissue re-generation, enhancement, or tissue repair. Electrospinning or other methods are used to create mats comprised of fibers that can be seeded with cells and subsequently rolled into a desired shape/form to replace a desired tissue.12-01-2011
20100166819Transforming Growth Factor Modulators - The invention is related to compounds of formula (I) that can be used as antagonists of the TGFβ family type I receptors, Alk5 and/or Alk4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.07-01-2010
20090324669OSTEOGENIC ENHANCER COMPOSITION - An osteogenic enhancer composition for bone and cartilage repair and methods of using the same are described.12-31-2009
20080317807STRONTIUM FORTIFIED CALCIUM NANO-AND MICROPARTICLE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Compositions containing strontium fortified calcium nanoparticles and/or microparticles, and methods of making and using thereof are described herein. The strontium fortified calcium compounds contain calcium ions, calcium atoms, strontium ions, strontium atoms, and combinations thereof and one or more anions. Exemplary anions include, but are not limited to, citrate, phosphate, carbonate, and combinations thereof. The particles can be formulated for enteral or parenteral administration by incorporating the particles into a pharmaceutically carrier. The compositions can further contain one or more active agents useful for bone diseases or disorders, such as vitamin D, growth factors, and combinations thereof. The compositions can be used to treat or prevent one or more bone diseases or disorders of the bone, such as osteoporosis. Alternatively, the particles can be coated onto a substrate, such as the surface of an implant. The coatings can be used to improved biocompatibility of the implant, prevent loosening of the implant, reducing leaching of metal ions from metallic implants, and reduce corrosion. The coatings can be applied to the substrate using a variety of techniques well known in the art. In one embodiment, the coating is applied using electrophoretic deposition. The use of nano- and/or microparticles that provide high surface area helps to improve interfacial strength between the coating and the implant, which allows for the use of lower sintering temperatures. Lowering sintering temperatures minimizes or prevents thermal decomposition of the coating material and/or degradation of the implant material.12-25-2008
20100291170NOVEL THERAPIES FOR CHRONIC RENAL FAILURE - The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins.11-18-2010
20100158968CELL-PERMEANT PEPTIDE-BASED INHIBITOR OF KINASES - The described invention provides kinase inhibiting compositions containing a therapeutic amount of a therapeutic inhibitor peptide that inhibits at least one kinase enzyme, methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression using the kinase inhibiting compositions.06-24-2010
20090214611Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions.08-27-2009
20090297573Identifying and Modulating Molecular Pathways that Mediate Nervous System Plasticity - The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacological agents that modify plasticity. The invention also identifies biological pathways that are enriched in genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The present invention further provides methods and compositions for modifying plasticity in the nervous system of a subject. The invention includes a method for modifying plasticity in the nervous system of a subject comprising administering a plasticity-modifying agent to the subject, wherein the plasticity-enhancing agent modulates a gene or pathway that is differentially regulated in developmental conditions that alter nervous system plasticity (e.g., DR or MD). The methods and compositions may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.12-03-2009
20100034861DISPERSIONS OF NANOUREAS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS - The present invention relates to dispersions of nanoureas comprising biologically active compounds, a process for their preparation, and their use.02-11-2010
20100034860Intra-Oral Device for Treating Obesity - The present invention relates to an intra-oral device including a carrier that has an outside wall, an inside wall and an occlusal wall connecting the outside wall to the inside wall. The carrier has at least one inset and at least one insert carrying a beneficial agent that is adapted to fit the inset, and the beneficial agent is capable of promoting weight loss. The intra-oral device is positioned in a user's mouth so that the intra-oral device is in contact with the user's cheeks, lips and/or tongue and the beneficial agent passes through the mucosal membrane of the user's mouth.02-11-2010
20110217350SUBSTRATE HAVING A SURFACE FOR INHIBITING ADHESION OF A TARGET CELL THEREON AND A METHOD OF PREPARING THE SAME - A substrate having a surface for inhibiting adhesion of a target cell thereon, the substrate comprising an array of generally longitudinal projections having a longitudinal axis that extends from the surface of said substrate and having an aspect ratio of at least 2.5, wherein adjacent projections of said array are configured on the substrate such that the projections at least partially inhibit adhesion of a target cell thereon.09-08-2011
20110217349SYSTEM AND METHOD FOR SUPPORTING A BIOLOGICAL CHIP DEVICE - A support apparatus for maintaining, storing, and transporting biological materials, such as cells. In accordance with certain embodiments of the invention, the biologic materials may be integrated to an electronic component to form a biological chip device, which may be supported, transported, and adapted for interconnection with other such devices through the use of a support apparatus in accordance with embodiments of the invention. In certain embodiments, the support apparatus can generate signals and/or translate signals received for processing and/or relaying to another device or module (e.g., another support apparatus). A plurality of biological chip devices and associated support apparatuses can be supported and linked in a network to perform various desired functions.09-08-2011
20090098176MEDICAL DEVICES WITH TRIGGERABLE BIOADHESIVE MATERIAL - Described herein are implantable medical devices comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. The triggerable bioadhesive property of the polymer can be triggered or activated by exposure to a stimulus. Also, the present invention pertains to methods of making an implantable medical device comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue.04-16-2009
20090098177Methods and devices for tissue repair - Methods for treating diseased or damaged tissue in a subject are disclosed, involving administering to said subject at a site wherein diseased or damaged tissue occurs, cells of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and/or suitable progenitor cells thereof, in association with bioresorbable beads or particles and optionally a gel and/or gel-forming substance. Where the cells an/or suitable progenitor cells thereof are chondrocytes, embryonic stem cells and/or bone marrow stromal cells, the methods of the invention are suitable for treating, for example, articular cartilage degeneration associated with primary osteoarthritis. Also disclosed is a device having tissue-like characteristics for treating diseased or damaged tissue in a subject, wherein the device comprises cells of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and/or suitable progenitor cells thereof, in association with bioresorbable beads or particles and optionally a gel and/or gel-forming substance.04-16-2009
20110262515FENESTRATED WOUND REPAIR SCAFFOLD - Fenestrated wound repair scaffolds and methods for forming scaffolds involve dispersing human collagen having a preserved amount of native constituents in solution, depositing the human collagen dispersion in a tray, forming openings in the collagen dispersion and removing the liquid component to form a fenestrated wound repair scaffold. Fenestrated wound repair scaffolds include a network of openings passing linearly through the wound repair scaffold to form channels for cells to pass into so as to form a series of cell formations therein.10-27-2011
20100112027Penis Enlargement - A method for causing a permanent increase in the length and girth of a male subject's penis, the method comprising treatment comprising the step of (a) administering to the male an effective amount of a vasodilator selected from the group consisting of a vasodilator per se and compositions thereof comprising a pharmaceutically-acceptable diluent or carrier, to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause the increase during the treatment. A potentiator which enhances the effect of the vasodilator may also be used.05-06-2010
20100112026SURFACES, METHODS AND DEVICES EMPLOYING CELL ROLLING - In various aspects, the present invention provides surfaces and materials for cell rolling applications, methods of making such surfaces and materials, and devices having such surfaces and materials. In some embodiments, the present invention provides surfaces with at least partial coatings of an ordered layer of cell adhesion molecules, or fragments, analogs, or modifications thereof, covalently bound to the surface of the substrate through an immobilization moiety. In some embodiments, the layer of a cell adhesion molecules further comprises a cell modifying ligand that can be targeted, e.g., to one or more specific cell types.05-06-2010
20090148488BIOACTIVE COATING FOR MEDICAL DEVICES - A medical device (and method for making same) comprising a passivating coating comprising keratin.06-11-2009
20100119570Solid Pharmaceutical And Vaccine Dose - An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described.05-13-2010
20100119568Apparatus and method for transdermal delivery of parathyroid hormone agents - An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.05-13-2010
20080260790Plasmid Enhancement Agent for High Intensity Focused Ultrasound Treatment and Use Thereof - The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the enhancement agent comprises a discontinuous phase is comprised of a core material encapsulated by a membrane-forming material, and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and has a particle size ranging from 10-1000 nm; the amount of the membrane-forming material in the enhancement agent is 0.1-100g/L; and the core material comprises nanometer-sized biocompatible solid selected from the group consisting of magnetic biomaterials, hydroxylapatite, and calcium carbonate, and the amount of the core material in the enhancement agent is 0.1-150 g/L.10-23-2008
20100266655SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDS - The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.10-21-2010
20100080835IMPLANTABLE DEVICE FOR THE DELIVERY OF RISPERIDONE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of risperidone to tissues or organs.04-01-2010
20120087969Mu-Conotoxin Peptides and Use Thereof as a Local Anesthetic - In one embodiment, the present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. An embodiment of the invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.04-12-2012
20090087469ALGINATE-BASED NANOFIBERS AND RELATED SCAFFOLDS - Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning.04-02-2009
20090087470CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.04-02-2009
20100080836METHOD AND MEANS FOR CULTURING OSTEOBLASTIC CELLS - A method of culturing human or mammalian mesenchymal stem cells (MSC) or osteoblastic cells to form corresponding cell aggregates evenly distributed in the culturing medium having a reduced content of cells with fibroblast morphology comprises contacting MSC or OC with a water-soluble cellulose derivative over a period of from 1 day to one or two weeks. Also disclosed are a corresponding aggregates, a culture medium and a pharmaceutical composition, and uses of the aggregate, the culturing medium and the composition.04-01-2010
20090263443METHODS FOR TREATING POST-OPERATIVE EFFECTS SUCH AS SPASTICITY AND SHIVERING WITH CLONDINE - Effective treatments of spasticity and shivering that accompanies surgeries are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relax muscle fibers. This administration of clonidine or a pharmaceutically acceptable salt thereof is particularly useful following the surgery.10-22-2009
20090263442Post Biopsy Cavity Treatment Implants and Methods - A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.10-22-2009
20090263445MEDICAL DEVICES COMPRISING SPRAY DRIED MICROPARTICLES - An implantable or insertable medical device which includes (a) a tacky polymeric region and (b) spray dried microparticles, which are adhered to the tacky polymeric region. The present invention is further directed to methods of forming such medical devices, and methods of releasing a therapeutic agent within a patient using such medical devices.10-22-2009
20090263444Fluocinolone Formulations in a Biodegradable Polymer Carrier - Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.10-22-2009
20090263441DRUG DEPOTS HAVING DIFFREENT RELEASE PROFILES FOR REDUCING, PREVENTING OR TREATING PAIN AND INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.10-22-2009
20100098736CONNECTIVE TISSUE REPAIR - The invention concerns a human stem cell isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof.04-22-2010
20090258047Heparin Prodrugs and Drug Delivery Stents Formed Therefrom - A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.10-15-2009
20090274736Nutraceutical Compositions From Microalgae And Related Methods of Production And Administration - Provided herein are polysaccharide compositions and methods of culturing microalgae to produce polysaccharides. Also provided are methods of using polysaccharides for applications such as reducing cholesterol in mammals, inactivating viruses, stabilizing foods, and other uses. Also provided are transgenic algae capable of utilizing fixed carbon sources for energy. Also provided herein are novel nucleic acid sequences from red microalgae.11-05-2009
20090142385COMPOSITIONS FOR TREATING BONE DEFECTS - In certain described embodiments, implantable medical materials comprise a scaffolding material, a liquid organic binder, and entrapped calcium-containing particles. The medical materials can incorporate an osteoinductive factor such as a protein. The scaffolding material can bind the factor. In additional described embodiments, implantable medical materials include an osteoconductive scaffolding material, an incorporated osteoinductive factor, and a biodegradable barrier material effective to delay release of the factor from the scaffolding material. The scaffolding material can bind the factor. Also described a methods for preparing and implanting the described medical materials.06-04-2009
20110171281SOFT CAPSULE COMPOSITION AND METHOD OF USE - A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide.07-14-2011
20080206297POROUS COMPOSITE BIOMATERIALS AND RELATED METHODS - Synthetic composite materials for use, for example, as orthopedic implants are described herein. In one example, a composite material for use as a scaffold includes a thermoplastic polymer forming a porous matrix that has continuous porosity and a plurality of pores. The porosity and the size of the pores are selectively formed during synthesis of the composite material. The example composite material also includes a plurality of a anisometric calcium phosphate particles integrally formed, embedded in, or exposed on a surface of the porous matrix. The calcium phosphate particles provide one or more of reinforcement, bioactivity, or bioresorption.08-28-2008
20080206296INJECTABLE CALCIUM-PHOSPHATE CEMENT RELEASING A BONE RESORPTION INHIBITOR - The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.08-28-2008
20110076314HYDROPHOBIC POLYSACCHARIDES WITH SILYL ETHER LINKAGES HAVING ENHANCED DEGRADATION AND MEDICAL ARTICLES MADE THEREFROM - Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a silyl ether chemistry that facilitates degradation of the polymer. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.03-31-2011
20090297572Drug-Containing Implants And Methods of Use Thereof - The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.12-03-2009
20080213331METHODS AND DEVICES FOR RENAL NERVE BLOCKING - A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.09-04-2008
20100278891BI-PHASIC COMPRESSED POROUS REINFORCEMENT MATERIALS SUITABLE FOR IMPLANT - A high strength porous biphasic polymeric reinforcement material manufactured by a compression and/or sintering process is disclosed. The material results in a network of interconnected collapsed pores, which forces thin overlapping walls and passages to be created. The network provides permeable access for fluid migration throughout the material. The strength and/or permeability are advantageous for medical devices and implants.11-04-2010
20100278892HIGH AFFINITY METAL-OXIDE BINDING PEPTIDES WITH REVERSIBLE BINDING - A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and found to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment of the proteins, cells and fusion proteins to solid material structures. The peptides can be used to functionalize surfaces of components within mechanical, in mechanical, biomechanical, micro fluidic, electronic, bioelectronic, bio-optical, and biochemical devices. Experiments were carried out to assess functionalization and reusability of a suspended mass resonator's cantilever.11-04-2010
20100221301Method for Preparing Porous Scaffold for Tissue Engineering - The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprise the steps consisting of a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide and one cross-linking agent b) freezing the aqueous solution of step a) c) sublimating the frozen solution of step b). characterized in that step b) is performed before the cross-linking of the polysaccharide occurs in the solution of step a).09-02-2010
20100143433Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein (BMP), such as BMP-6, containing a heparin binding site and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the bone morphogenetic protein for treating disorders related to bone and cartilage formation. The present invention further relates to osteogenic devices and pharmaceutical compositions containing the protein.06-10-2010
20090169591MEDICAL ARTICLES FOR THE TREATMENT OF TUMORS - In accordance with one aspect of the invention, implantable and insertable medical articles are provided which are useful for the local treatment of tumors. These medical articles comprise one or more active agents that influence the local tumor environment in vivo, for example, decreasing the level of nutrients in the local tumor environment, inhibiting the utilization of nutrients in the local tumor environment, decreasing the amount of molecular oxygen and/or reactive oxygen species in the local tumor environment, or increasing the amount of molecular oxygen and/or reactive oxygen species in the local tumor environment. Other aspects of the invention pertain to methods of treatment that employ such medical articles. Still other aspects of the invention pertain to methods of making such medical articles.07-02-2009
20080233162Fibrous 3-Dimensional Scaffold Via Electrospinning For Tissue Regeneration and Method For Preparing the Same - The present invention relates to a fibrous 3-dimensional porous scaffold via electrospinning for tissue regeneration and a method for preparing the same. The fibrous porous scaffold for tissue regeneration of the present invention characteristically has a biomimetic structure established by using electrospinning which is efficient without wasting materials and simple in handling techniques. The fibrous porous scaffold for tissue regeneration of the present invention has the size of between nanofiber and microfiber and regular form and strength, so that it facilitates 3-dimensional tissue regeneration and improves porosity at the same time with making the surface area contacting to a cell large. Therefore, the scaffold of the invention can be effectively used as a support for the cell adhesion, growth and regeneration.09-25-2008
20100129413METHOD OF TREATING AND PREVENTING VIRAL INFECTIONS - A method for treatment of a viral infection in a mammal comprising a step of administering a composition containing an amount of selenium (Se) effective to raise the serum level of the mammal to at least 15 μg/L above baseline.05-27-2010
20120294924Peptide-Lipid Conjugates And Uses Thereof - Disclosed are peptide-lipid conjugates that bind lipopolysaccharide. Also disclosed are methods of making and using the peptide-lipid conjugates.11-22-2012
20080279906Treatment of Amyotrophic Lateral Schlerosis - The present invention relates to the treatment of motoneuron diseases. More particularly the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a preclinical ALS animal model induces a significant motor performance and prolongation of survival time of said animals.11-13-2008
20080279907Antimicrobial medical devices and methods for making and using same - In general, this application is directed to medical devices that exhibit antimicrobial activity and to methods for preparing and using the medical devices. The medical devices of the present application include a polymeric portion that has been impregnated with a paraben and an organic dye in a manner whereby the paraben and organic dye exhibiting antibacterial properties. In one form, the paraben is impregnated into the polymeric portion before impregnation thereof with the organic dye. In another form, it is contemplated that the polymeric material may include methyl paraben, propyl paraben, and methylene blue. It is further contemplated that the polymeric material is effective in releasing at least one of the paraben and organic dye to prohibit bacterial growth in surrounding tissue and/or fluid.11-13-2008
20080286322METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.11-20-2008
20110268781DRUG ELUTING COMPOSITE - The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.11-03-2011
20100297209SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES - A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.11-25-2010
20080248077Formulation - The present invention relates to slow release anastrozole formulations, more particularly to biodegradable polymers, typically a polylactide or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated, including microparticle formulations and monolithic implant formulations. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer.10-09-2008
20100203099MULTI-DOMAIN AMPHIPATHIC HELICAL PEPTIDES AND METHODS OF THEIR USE - Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.08-12-2010
20100143434MECHANICALLY RESPONSIVE SUPPORTED POLYELECTROLYTE MULTILAYER FILMS - The invention concerns a mechanically responsive supported polyelectrolyte multilayer film, comprising:—an elastic substrate, on which are alternately coated:—at least one exponentially growing film; and—at least one mechanically responsive barrier film. It further concerns a process for its preparation and the use of such films notably for mechanically responsive mixing or delivery of active substances. It further concerns dosage forms of a drug, biosensors and implants comprising such films.06-10-2010
20100143437IMPLANTABLE ANALGESIC - A method and device for implantable analgesics having a plurality of analgesia containing portions that are capable of being sequentially released.06-10-2010
20100143436SELF-ASSEMBLY OF PROTEIN-BASED BIOMATERIALS WITH MULTIPLE MORPHOLOGIES - The present disclosure relates, in some embodiments, to a composition comprising a biomaterial. A biomaterial may comprise, for example, one or more molecules capable of self-association and/or self-assembly. In some embodiments, a biomaterial may comprise one or more polypeptides and/or proteins. A biomaterial may comprise, for example, two or more self-assembled Ultrabithorax (Ubx) protein molecules. A Ubx protein, in some embodiments, may be any wild type 06-10-2010
20100136080MATERIAL DEPOT FOR RELEASING AN ANTIBACTERIAL ACTIVE AGENT - The subject matter of the invention is a material depot which dispenses an antibacterial active ingredient material into a human or animal body via the surface of the depot. The surface of the material depot is larger than the envelope of the material depot. The increased surface of the material depot effects a higher level of the antibacterial active ingredient material at the location of the implant and permits effective destruction in situ of both sensitive pathological germs and partially resistant germs.06-03-2010
20100209468IMPLANTABLE DEVICES FOR PRODUCING INSULIN - The present invention generally relates to implantable devices for producing insulin in diabetic animals. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and/or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent or diminish an immuno-response and/or rejection by the host.08-19-2010
20090136556System And Method For Coating Implantable Devices - A method and system of coating an implantable device, such as a stent, are provided.05-28-2009
20100209467TDF-RELATED COMPOUNDS AND ANALOGS THEREOF, ANALOGS AND BIOACTIVE FRAGMENTS - The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.08-19-2010
20090136554Transdermal sustained release drug delivery - Provided herein are microprojections and microprojection arrays for delivering biologically active agents. Also provided herein are compositions suitable for coating such microprojections and microprojection arrays.05-28-2009
20080213330Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons - A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.09-04-2008
20090117166Sequential coupling of biomolecule layers to polymers - A bio-mimetic or bio-implantable material based on a sequential process of coupling biomolecule layers to a polymer layer is provided. In general, the material could be based on two or more biomolecule layers starting with one of the layers covalently linked to the polymer layer via cross-linkers and the other layers sequentially and covalently linked using cross-linkers to the previously added layer. The polymer layer could be a hydrogel or an interpenetrating polymer network hydrogel. The first layer of biomolecules could be a collagen type, fibronectin, laminin, extracellular matrix protein, or any combinations thereof. The second layer of biomolecules typically is a growth factor, protein or stimulant. The cross-linkers are either water soluble or insoluble bifunctional cross-linkers or azide-active-ester crosslinkers. The material and process as taught in this invention are useful in the field of tissue engineering and wound healing.05-07-2009
20120141572Surface Coating for Biomedical Implants and Electrodes - An implantable device is described based on an implant having a textured outer surface of polymer material with limited transparency. A smooth outer polymer coating covers and cross-links with the textured outer surface to form a coated implant of greater transparency than the polymer material of the implant.06-07-2012
20090162412IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.06-25-2009
20090136552Growth factors nsg28, nsg30, and nsg32 - Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.05-28-2009
20090092650Sustained Delivery Formulations of Octreotide Compounds - The present invention relates to an octreotide sustained release delivery system for treatment of diseases relating to somatotropin and/or somatostatin. The sustained release delivery system of the invention includes a flowable composition containing an octreotide compound, and an implant containing the octreotide compound. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and an octreotide compound.04-09-2009
20090186059DEVICES AND METHODS FOR ELUTION OF NUCLEIC ACID DELIVERY COMPLEXES - Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a method of making a medical device. The method can include complexing nucleic acids with a carrier agent to form a delivery complex solution, applying the delivery complex solution to a substrate, and applying a polymeric solution to the substrate. In another embodiment, the invention includes a method of making a medical device including complexing nucleic acids with a carrier agent to form nucleic acid delivery complexes, combining the nucleic acid delivery complexes with a polymer solution and a cross-linking agent, wherein the cross-linking agent is positively charged or charge neutral. In an embodiment, the invention includes an implantable medical device including a substrate and a coating disposed on a surface of the substrate, the coating comprising a polymeric matrix and a plurality of disperse nucleic acid delivery complexes disposed within the polymeric matrix. Other embodiments are included herein.07-23-2009
20080317806Antiparasitic Compounds - A compound of Formula (A), wherein R12-25-2008
20080317805LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS - This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot.12-25-2008
20090208550Methods and compositions for treating hepatic diseases - The invention provides methods and compositions for treating a hepatic disease, for reducing fat deposition in the liver and for inhibiting fibrosis of the liver by administering a compound or agent that modulates an adenosine receptor, in particular, an inhibitor or antagonist of an adenosine receptor, especially an A08-20-2009
20090324668IMPLANT, ITS USES AND METHODS FOR MAKING IT - An implant containing a source of oxygen capable of releasing oxygen in the form of molecular oxygen or reactive oxygen species, and a material selected from the group consisting of biodegradable and/or bioactive glass, sol-gel produced silica and mixtures thereof. Also disclosed are uses of the implant and methods of making it.12-31-2009
20110223229IMMOBILISED BIOLOGICAL ENTITIES - There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which anti-coagulant entity is covalently attached to said surface through a linker comprising a thioether.09-15-2011
20110142901SUSTAINED RELEASE COMPOSITION - A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist.06-16-2011
20090053276INJECTABLE HYDROGEL COMPOSITIONS - In accordance with one aspect of the invention, injectable compositions are provided, which contain temperature-sensitive hydrogel particles. The hydrogel particles may be provided in dry form, or they may be provided in hydrated form in an aqueous fluid. The temperature-sensitive hydrogel particles may have an upper critical solution temperature (UCST) below normal body temperature, they may have a lower critical solution temperature (LCST) above normal body temperature, or they may have a LCST that changes from below normal body temperature to above normal body temperature after injection into a subject.02-26-2009
20110142902Hypoxia Inducing Factor (HIF) Stabilising Glasses - The present invention relates to a glass composition formulated to provide the controlled release of certain transition metal ions to regulate the cellular hypoxia pathway and the use of these hypoxia-pathway regulating glasses in medicine and in biomedical research, including in the repair, restoration or regeneration of diseased or damaged tissue.06-16-2011
20110223230HYDROGEL FORMULATIONS - A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.09-15-2011
20090017088IMPLANT AND SYSTEM OF AN IMPLANT AND A EXCITATION DEVICE - An implant comprising a body (01-15-2009
20090004238IMPLANTATION OF ENCAPSULATED BIOLOGICAL MATERIALS FOR TREATING DISEASES - Methods of applying biocompatible coating materials around biological materials using photopolymerization while maintaining the pre-encapsulation status of the biological materials are disclosed. The coatings can be placed directly onto the surface of the biological materials or onto the surface of other coating materials that hold the biological materials. The components of the polymerization reactions that produce the coatings can include natural and synthetic polymers, macromers, accelerants, cocatalysts, photoinitiators, and radiation. Methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site are also disclosed. The coating materials can be manipulated to provide different degrees of biocompatibility, protein diffusivity characteristics, strength, and biodegradability to optimize the delivery of biological materials from the encapsulated implant to the host recipient while protecting the encapsulated biological materials from destruction by the host inflammatory and immune protective mechanisms without requiring long-term anti-inflammatory or anti-immune treatment of the host.01-01-2009
20100003297Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues - A method is provided for local controlled delivery of a drug to the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of a patient in need of treatment. In one embodiment, the method includes implanting a resorbable drug delivery device within the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of the patient. The drug delivery device may include an elastic device body housing at least one drug reservoir which contains at least one drug. In a preferred embodiment, the method further includes releasing the drug from the device in a controlled manner to, typically directly to, the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens.01-07-2010
20080260793POROUS GELATIN MATERIAL, GELATIN STRUCTURES, METHODS FOR PREPARATION OF THE SAME AND USES THEREOF - The present invention relates to a porous gelatin material in the form of spherical particles with a continuous pore structure and cast, three-dimensional, porous gelatin structures. The invention also comprises methods for preparation of the porous gelatin materials and structures. The method for preparing the porous gelatin material in the form of spheres with a continuous pore structure comprises the steps of preparing a homogenous water-based gelatin solution, adding an emulsifier with an HLB value >9, adding a first composition comprising an organic solvent and an emulsifier with an HLB value >9, adding a second composition comprising an organic solvent and an emulsifier with an HLB value <8 and allowing the gelatin material to solidify. Uses of the materials according to the invention are also included.10-23-2008
20080260792Method to Use Therapeutic Microencapsulation of Embedding Parathyroid Live Cells with Theracyte - A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in −179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×1010-23-2008
20080260791Injectable capsaicin - The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 μg to 3000 μg.10-23-2008
20100015195INJECTABLE DEPOT COMPOSITIONS AND IT'S PROCESS OF PREPARATION - Novel injectable depot compositions are provided comprising at least one active agent(s) optionally with one or more pharmaceutically acceptable excipient(s) in the form of a multi-component system preferably comprising at least two components which when administered to a subject in need thereof forms an in situ gel depot or implant at the site of injection upon contact with body fluids. Also described are process for preparation of such compositions and method of using such compositions.01-21-2010
20090148485Controlled Release Devices and Structural Elements for Use in Their Manufacture - A structural element (06-11-2009
20100183695Cerberus/coco derivatives and uses thereof - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.07-22-2010
20100239631THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF - The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.09-23-2010
20100215708COATING OF DEVICES WITH EFFECTOR COMPOUNDS - This invention is directed to substrates, materials and devices coated with a gel, foam, film, particle or composition comprising a polymei solvent and effector compounds attached thereto, processes of producing the same, and methods of use thereof, of in, inter-alia, biological applications, including preventing infection and the treatment of various diseases.08-26-2010
20100226953MEDICAL DEVICES HAVING A COATING OF BIOLOGIC MACROMOLECULES - A medical device having a coating of biologic macromolecules. The coating of biologic macromolecules is protected by a temporary protective layer disposed over the biologic macromolecules. The temporary protective layer serves to protect the structure (e.g., conformation) and/or function (e.g., target binding capacity) of the biologic macromolecules during processing, storage, handling, and/or delivery (e.g., implantation or insertion into a patient) of the medical device. Upon implantation or insertion into a patient's body, the temporary protective layer may dissolve to expose the biologic macromolecules to the physiologic environment.09-09-2010
20100255051POLYKETAL POLYMERS, AND METHODS OF MAKING AND USING SAME - Polyketal polymers, and methods of making and using such polyketal polymers are disclosed herein. The polyketal poylmers can be useful for applications including, for example, medical devices and pharmaceutical compositions. In a preferred embodiment, the polyketal polymers are biodegradable.10-07-2010
20100143435SCAFFOLD WITH INCREASED PORE SIZE - The invention relates to scaffolds for use as medical devices, for guided tissue regeneration and repair, wherein the relationship between fibre diameter and pore size in a scaffold is decoupled, thereby enabling the small fibre diameters required for cell attachment and proliferation and the large pore sizes needed for cell migration into the scaffold to be achieved.06-10-2010
20100260815FLUID CONCENTRATOR, AUTOLOGOUS CONCENTRATED BODY FLUIDS, AND USES THEREOF - The present invention provides devices and methods for concentrating a fluid and for treating a patient with the concentrated fluid. The concentrator apparatus includes a main housing (10-14-2010
20090074829Novel Heparin Alternative Material and Method for Producing the Same - The object is to provide a novel heparin alternative material, which is excellent in safety and in vivo degradability. Disclosed are: a novel heparin alternative material, which comprises an enzymatically synthesized α-1,4-glucan derivative and has functions substituting those of heparin, such as an anticoagulation activity and functions of a material for storage or sustained release of a heparin-binding growth factor; a method for production of the substitute material; and a preparation or article for medical applications or a cosmetic produced using the heparin alternative material.03-19-2009
20100221300Processing of Angiogenic Scaffolds for Large Organ Regeneration - This invention relates to a method for fabricating large scaffolds in a variety of shapes with an organized pore structure. The pore structure is organized such that pores are generally aligned perpendicular to the edges of the scaffold, regardless of-the particular macroscopic scaffold shape. Specifically, a freeze-drying based fabrication method for creating large, polymeric porous scaffolds for tissue engineering applications, with an organized pore structure of columnar pores extending from the scaffold periphery into the main mass of the scaffold.09-02-2010
20110177150IMPLANTABLE TISSUE COMPOSITIONS AND METHOD - Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed.07-21-2011
20090110709ELASTIN PROTECTIVE POLYPHENOLICS AND METHODS OF USING THE SAME - Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.04-30-2009
20100303879SILANE-FUNCTIONALIZED HYDROPHOBIC a(1-4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION - Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices are described. Biodegradable matrices can be formed from hydrophobic α(1→4)glucopyranose polymers with reactive pendent silyl ether groups. Reaction of the silyl ether groups provides improved matrix formation through bonding to a device surface of a device, polymer-polymer crosslinking, or both. Biodegradable matrices can be used for the preparation of implantable and injectable medical devices, including those that release a bioactive agent.12-02-2010
20110123590Selective Expansion of Regulatory T Cells - Methods for expanding regulatory T cells in vitro are provided. It has been discovered that regulatory T cells can be expanded in vitro by culturing a mixed population of lymphocytes on planar cell culture substrates, for example cell culture dishes, coated with binding partners for TCR complex and CD05-26-2011
20100303878BIODEGRADABLE BIOACTIVE AGENT RELEASING MATRICES WITH PARTICULATES - The present invention is directed to biodegradable polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the biodegradable matrices include an aliphatic polyester copolymer and microparticulates that include the hydrophilic bioactive agent. In some embodiments, the matrix includes a second biodegradable polymer comprising hydrophilic and hydrophobic portions. Exemplary matrix forms are device coatings and medical implants. Matrices of the invention demonstrated high bioactive agent loading, were able to modulate release of the bioactive agent in a therapeutic manner, and also maintained high levels of activity for therapeutically useful large molecule bioactive agents, such as proteins.12-02-2010
20090068243Novel formulations for delivery of antiviral peptide therapeutics - Provided herein are compositions and methods for their administration as therapeutic agents. In particular, provided herein are compositions and their use for the administration of antiviral peptide therapeutics.03-12-2009
20110008404Modification Of Biomaterials With Microgel Films - The various embodiments of the present disclosure relate generally to the modification of biomaterials with microgel films. More particularly, the various embodiments of the present invention are directed to the modification of biomaterials and medical devices with microgel thin films to alter a host's response to an implanted biomaterial or medical device. An embodiment of the present invention comprises a coated biomaterial comprising a non-fouling polymer film attached to at least a portion of a surface of the biomaterial, the non-fouling polymer film comprising a plurality of a cross-linked polymer microparticles, wherein at least a portion of the cross-linked polymer microparticles are covalently bonded to at least a portion of the surface of the biomaterial.01-13-2011
20110111002TRANSPORT AND DELIVERY OF GLUTATHIONE INTO HUMAN CELLS USING GOLD NANOPARTICLES - A method of using specially designed a nanoparticles to contact and then cross the cell, nuclear and/or mitochondrial membrane of the target cell by generating a multitude of complex nanoparticle structures that resonate or vibrate at a specific frequency. Glutathione and/or other molecules or drugs are attached as molecular layers to the nanoparticle structures and the complex particle structures are delivered to the targeted cells. The glutathione and other molecules or drugs are then released from the nanoparticle structures in the destination target cell by using external radiation.05-12-2011
20110111003STABLE CELL BINDING CHIMERIC PEPTIDES - The present invention relates to novel family of homologous cell attachment chimeric peptides. In particular, the present invention relates to chimeric peptides, each comprising synthetic peptides comprising (a) an M-tide comprising an amino acid sequence that is at least 80% homologous to the amino acid sequence selected from the group consisting of: SEQ ID NO:1, 2 and 37; and (b) a core haptide comprising an amino acid sequence homologous to amino acid sequences at the carboxy termini of the and E chains of fibrinogen or other proteins comprising C-termini that are homologous to said fibrinogen sequences, wherein the M-tide and the core haptide originate from the same protein. The synthetic peptides are linked to one another thereby providing the chimeric peptides of the invention which does not occur in the native protein as a continuous sequence. The present invention further discloses pharmaceutical compositions comprising said chimeric peptides and uses thereof.05-12-2011
20110033515TISSUE CONTACTING MATERIAL - A tissue contacting material comprising a plurality of regions comprising an outer region serving as a protective barrier, one or more inner regions, and a tissue contacting region. The plurality of regions each comprise one or more of a plurality of polymers selected from the group consisting of a first polymer comprising a crosslinked hydrophilic polymer and a second crosslinked polymeric matrix, formed of a crosslinkable polymer adapted to incorporate the first polymer without substantially reacting or crosslinking with the first polymer. The first and/or second polymers provide the respective regions with one or more properties including swellability in the presence of water, active agent content, permeability to the diffusion of active agent from or through the layer, moisture vapor permeability, and adhesion to tissue.02-10-2011
20110117160ANTAGONISTIC PROPERTIES OF REEF FISH MICROFLORA - The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.05-19-2011
20090074828POLY(AMINO ACID) TARGETING MOIETIES - The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.03-19-2009
20090311297Biocompatible Transparent Sheet, Method for Producing the Same, and Cultured Cell Sheet Used the Same Sheet - The present invention provides a flexible, biocompatible transparent sheet (12-17-2009
20110129513COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.06-02-2011
20100062034MEMBRANE SHELL OF AN IMPLANTABLE DOSAGE SYSTEM - The membrane shell of an implantable dosage system according to the invention is particularly suitable for subcutaneous applications to release an active agent with steady amounts during a longer period of time. The membrane shell (03-11-2010
20090214612EXTRACELLULAR TNF INHIBITORS FOR TREATING CNS DISORDERS - Methods and devices to attenuate tumor necrosis factor (TNF) and other pro-inflammatory mediators in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, and brain injury are described. More particularly, TNF blocking agents that target TNF-receptor interactions and the effects of downstream secreted cytokines associated with an inflammatory cascade are described. Such TNF blocking agents are administered directly to the brain by, for example, intraparenchymal administration, intracerebroventricular administration, or administration into a cerebral artery. Devices described include therapy delivery devices comprising a reservoir capable of housing a TNF blocking agent and a catheter operably coupled to the device and adapted to deliver the TNF blocking agent to a target site within a subject.08-27-2009
20110081394METHODS OF ATTACHING A MOLECULE-OF-INTEREST TO A MICROTUBE - Provided is a method of attaching a molecule-of-interest to a microtube, by co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming a coat over an internal surface of the shell, the first polymeric solution is selected solidifying faster than the second polymeric solution and a solvent of the second polymeric solution is selected incapable of dissolving the first polymeric solution and wherein the second polymeric solution comprises the molecule-of-interest, thereby attaching the molecule-of-interest to the microtube. Also provided is an electrospun microtube comprising an electrospun shell, an electrospun coat over an internal surface of the shell and a molecule-of-interest attached to the microtube.04-07-2011
20110070280METHOD FOR DIFFERENTIATING EMBRYONIC STEM CELLS INTO CELLS EXPRESSING AQP-1 - The present invention relates to methods of differentiating a human embryonic stem (ES) cell into a cell, specifically a renal epithelial cell, expressing AQP-I. The methods disclosed comprise culturing human ES cells in a renal specific medium in the presence of an extracellular matrix molecule. The cells produced according to said method can be used to treat renal related disorders such as renal failure, nephrosis, Bright's disease and glomerulitis.03-24-2011
20110070281REPARATIVE CELL DELIVERY VIA HYALURONIC ACID VEHICLES - Methods are described for generating autologous tissue grafts, including generating grafts at the point of case, which include isolated cell populations that are enriched with stem cells and are mixed with hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.03-24-2011
20120148654METHOD AND SYSTEM FOR A PHOTORESIST-BASED IMMUNOISOLATIVE MICROCONTAINER WITH NANOSLOTS DEFINED BY NANOIMPRINT LITHOGRAPHY - The present technology provides a system and/or method for a photoresist-based immunoisolative microcontainer with nanoslots defined by nanoimprint technology. The present technology further provides a method of immunoisolating one or more biomolecules, the method comprising providing a biocompatible microcontainer, wherein the microcontainer comprises a base and semi-permeable nanoporous surface. Methods of using the microcontainers for transplantation and cell therapy are also described.06-14-2012
20100310622DRY EYE TREATMENT BY PUNCTA PLUGS - A punctal plug and method of treating dry eyes are provided. The punctal plug has two or three layer structure and contains at least one drug, for treating conditions such as dry eyes contained in a core, a potion of which is covered by a drug impermeable shell such that drug can radially diffuse from the core. The punctal plug can be inserted into a patient's upper punctum, lower punctum, or both to deliver the drug for an extended period of time. The drug for treating dry eyes can be, for example, cyclosporine A. The plug can also be used for extended delivery of ophthalmic drugs.12-09-2010
20100297208SCAFFOLD - The present invention relates to scaffolds which can be used as medical devices for guided tissue regeneration and repair, in particular the invention is directed to a scaffold comprising fibres having a mean fibre diameter of between from about 1.2 to 4.0 microns, wherein the fibres comprise a glycolide. The invention further relates to the use of the scaffolds for the selective capture of cell populations for a cell source material.11-25-2010
20110045046GLYCOPEPTIDES AND METHODS OF MAKING AND USING THEM - In one embodiment, the invention provides glycopeptides (or carbohydrate-peptide conjugates) comprising TACAs that direct against (e.g., bind specifically to) cytotoxic T lymphocytes (CTLs) or helper T cells for, e.g., CTL- or T-helper-based immunotherapy of carcinomas, and methods for making and using the glycopeptides of the invention. In one embodiment, the invention provides novel glycopeptides comprising tumor-derived carbohydrate or tumor-derived epitopes that specifically bind to major histocompatibility (MHC) class I molecules on cytotoxic T lymphocytes (CTLs) or MHC molecules on helper T cells, and methods for using same, e.g., as a vaccine, including a pan-cancer vaccine.02-24-2011
20110045045Production of and uses for decellularized lung tissue - The present invention provides a process of producing a decellularized extracellular matrix DC lung from native lung tissue using rapid freeze/thaw cycling to induce cellular damage and the constant circulation of a detergent or peracetic acid and enzymatic digestion with DNAase/RNAase within a continuously rotating bioreactor. Also, provided are methods to produce a functional engineered lung tissue on the DC lung using endogenous lung progenitor cells. In addition, a composition comprising the DC lung and the endogenous lung progenitor cells seeded therein or thereon and an implantable composition comprising the functional engineered lung tissue which are useful in methods of treating a lung to restore at least some function thereto.02-24-2011
20110045044COMPOSITIONS FOR REPAIR OF DEFECTS IN TISSUES, AND METHODS OF MAKING THE SAME - Tissue repair compositions, particularly bone repair compositions, containing (a) bone fragments and (b) homogenized connective tissue, and methods for making the same are provided. Some of the inventive tissue repair compositions contain a radioprotectant. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form. Kits for using such tissue repair compositions are also provided.02-24-2011
20090317439Cell Preparations for Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides compositions comprising plasma or platelet-rich plasma alone or in combination with cell preparations for use in tissue regeneration and bone regeneration and pain reduction.12-24-2009
20110165215COHESIVE OSTEOGENIC PUTTY AND MATERIALS THEREFOR - Described is an implantable medical material comprising a malleable, cohesive, shape-retaining putty including mineral particles, insoluble collagen fibers and soluble collagen. The medical material can be used in conjunction with biologically active factors such as osteogenic proteins to treat bone or other tissue defects in patients.07-07-2011
20110020418Particulate Tissue Graft with Components of Differing Density and Methods of Making and Using the Same - Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient.01-27-2011
20110027331AN IMPLANTABLE DRUG DEPOT HAVING A REVERSIBLE PHASE TRANSITION MATERIAL FOR TREATMENT OF PAIN AND/OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided that utilize a reversible phase transition material of a drug depot. When heat, cold or another suitable form of energy, e.g., ultrasound energy is applied to the reversible phase transition material, the release of an analgesic and/or anti-inflammatory agent from a drug depot is increased.02-03-2011
20100285082Integrated Biosensor and Simulation System for Diagnosis and Therapy - BioMEMS/NEMS appliance biologically monitors an individual, using biosensors to detect cellular components. Data is simulated or analyzed using systems-biology software, which provides diagnostic or therapeutic guidance.11-11-2010
20100330143MODIFIED MACROMOLECULES AND METHODS OF MAKING AND USING THEREOF - Described herein are composites produced by reacting a first thiolated macromolecule with at least one compound having at least one thiol-reactive electrophilic functional group. The methods described herein permit the cross-linking of a variety of different thiolated macromolecules with one another. The composites described herein have a variety of biomedical and pharmaceutical applications, which are also described herein.12-30-2010
20110256201HYDROLYZED HYDROGELS - The invention provides methods of making hydrolyzed cross-linked polyvinyl alcohol (PVA) hydrogels by polymerizing vinyl acetate (VAc) monomers to polyvinyl acetate (PVAc) polymer network by chemical-crosslinking and hydrolysis. The invention also provides methods for including pendant chains in the hydrogel during the polymerization process. Materials produced and use of the cross-linked hydrolyzed PVA hydrogels also are disclosed herein.10-20-2011
20110052657Implants for administering substances and methods of producing implants - A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant may have a large number of holes which contain beneficial substance and which are closed by bio-errordable doors of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached.03-03-2011
20100119571IMPLANTABLE DEVICES FORMED ON NON-FOULING METHACRYLATE OR ACRYLATE POLYMERS - Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.05-13-2010
20110097373BONE PROSTHETIC MATERIAL AND METHOD OF MANUFACTURING THE SAME - A method of manufacturing a bone prosthetic material, includes by forming tricalcium phosphate (TCP) particle precursor particles; by performing preliminary sintering on the TCP precursor particles at a temperature in a first temperature range to produce TCP particles of diameters in a predetermined diameter range; by granulating the TCP particles to produce granulated bodies; and by performing sintering on the granulated bodies at a temperature in a second temperature range to generate sinter assemblies. The second temperature range is higher than the first temperature range. In the bone prosthetic material manufactured thus, a first space in a range of 100 to 400 μm is formed between adjacent two of a plurality of sintered assemblies. Each of the plurality of sintered assemblies includes tricalcium phosphate (TCP) particles which are subjected to sintering, and a second space in a range of 5 to 100 μm is formed between adjacent two of the TCP particles. The second space communicates with the first space. Each of the plurality of sintered assemblies has a connection portion connecting the TCP particles, and the connection portion has a width in a range of 5 to 20 μm.04-28-2011
20110097372DEVICES, METHODS, AND COMPOSITIONS FOR CONTROLLING INFECTIONS - The subject invention provides novel and highly effective methods and devices for convenient and effective wound irrigation.04-28-2011
20100166820COPOLYMERS HAVING POLYISOBUTYLENE AND BIODEGRADABLE POLYMER SEGMENTS - The present invention pertains to copolymers having one or more polyisobutylene segments and one or more biodegradable polymer segments, to methods of making such copolymers, to medical articles that contain such copolymers, and to methods of making such medical articles. According to certain aspects of the invention, copolymers are provided, which comprise a plurality of polyisobutylene segments and a plurality of biodegradable polymer segments. According to certain aspects of the invention, copolymers are provided, which comprise urethane linkages, urea linkages, amide linkages, ester linkages, anhydride linkages, carbonate linkages, linkages commonly described as “click” chemistry linkages, and combinations of two or more types of such linkages.07-01-2010
20100158971METHOD FOR REDUCING THE LIKELIHOOD OF PREECLAMPSIA IN A SUBJECT IN NEED THEREOF - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo.06-24-2010
20100158970IMPLANTABLE COMPOSITES AND IMPLANTS COMPRISING SAME - Described herein are implantable composites, articles comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.06-24-2010
20100158972METHOD FOR REDUCING THE LIKELIHOOD OF PRETERM LABOR IN A SUBJECT IN NEED THEREOF - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo.06-24-2010
20100196433PREVASCULARIZED DEVICES AND RELATED METHODS - The present invention provides an implantable devices for providing a biologically active agent to a subject in need thereof, the device comprising a microvessel construct in contact with a biocompatible, semi-permeable pouch, the pouch encapsulating a cell or cells capable of producing the biologically active agent. The present invention also provides methods for treating or preventing a disorder in a subject using the implantable device. The present invention also provides specific methods for treating or preventing diabetes in a subject comprising implanting in the subject an immunoisolation device comprising a microvessel construct in contact with a biocompatible, semi-permeable pouch, the pouch encapsulating a cell or cells capable of producing a therapeutically effective amount of insulin. Methods for vascularizing and revascularizing tissue, including engineered tissue, are also provided.08-05-2010
20100196432BIOPOLYMER STRUCTURES - The invention described herein relates to biopolymer structures. The biopolymer structures are spatially organized from the nanometer to centimeter length scales and incorporate functionally active cells. Applications of the biopolymer structures include use with stem cells.08-05-2010
20110262516AUTOLOGOUS CELLS ON A SUPPORT MATRIX FOR TISSUE REPAIR - The present invention relates to a method for the effective treatment of tissue defects and for tissue regeneration. The method includes seeding autologous cells on a support matrix and implanting the cell-seeded support matrix into a site of transplantation. The present invention also relates to various tissue repair structures that include cells seeded onto a cell-free membrane. The present invention also provides methods for cultivation, seeding, and implantation of autologous cells.10-27-2011
20090202604Benzodiazepine Formulation in a Polyorthoester Carrier - Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.08-13-2009
20090175918Ultra-Passivation of Chromium-Containing Alloy and Methods of Producing Same - The invention concerns article having a surface oxide layer up to 20 nm thick, the surface oxide layer comprising chromium and cobalt oxides where the atomic ratio of Cr/Co is more than 3. The invention also concerns methods for treating a chromium containing material, said method comprising contacting said material with a gas plasma under conditions effective to oxidize at least a portion of the material; and contacting said material with an acid. The treated surface is corrosion resistant and can be used in orthopedic implants, especially the wear surface of the orthopedic implant to reduce wear, and other corrosive environment.07-09-2009
20100189757DRUG DEPOT IMPLANT DESIGNS AND METHODS OF IMPLANTATION - The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.07-29-2010
20110189252PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR TREATING HYPERPLASTIC DISEASES - The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from 08-04-2011
20100028399Use of Polymers - The present invention relates to the use of a thiol-group-containing polymer for preparing an implant for tissue augmentation, wherein the basis polymer is a polysaccharide.02-04-2010
20100028398CELL IMPLANTATION TO PREVENT AND/OR TREAT HEARING LOSS - The present invention is directed to the prevention or treatment of sensorineural hearing loss by administering a therapeutically effective amount of an implantable composition comprising encapsulated living choroid plexus cells.02-04-2010
20100028400PHARMACEUTICAL COMPOSITION ON THE BASIS OF STACHYTARPHETA SP., A PROCESS FOR OBTAINING THE SAME AND ITS USE FOR TREATING VITILIGO - This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plant of the 02-04-2010
20100021517NON-WOVEN FIBER FABRIC - In order to provide a non-woven fiber fabric, in particular, in the form of a flat material or as part of a flat material which can be used as a biodegradable material in medicine, in particular, as an implant or carrier material for living cells (tissue engineering) but also a non-woven fiber fabric which can be used in food technology in a variety of applications, in particular, as a preliminary product for foods, a non-woven fiber fabric is provided containing fibers consisting of a gelatin material, wherein the thickness of the fibers is on average 1 to 500 μm and wherein the non-woven fiber fabric has a plurality of areas, at which two or more fibers merge into one another without any phase boundary.01-28-2010
20090123509Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds - A colloid gel can include a plurality of positive charged particles mixed and associated with a plurality of negative charged particles so as to form a three-dimensional matrix having a plurality of pores defined by and disposed between the particles. The three-dimensional matrix can have shear thinning under shear and structure stability in the absence of shear. A method of manufacturing the colloid gel can include combining the positive charged particles with the negative charged particles, in a mold or in situ, so as to form the three-dimensional matrix having the plurality of pores.05-14-2009
20090136555PROCESS FOR THE PREPARATION OF A HOT-MELT EXTRUDED LAMINATE - A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.05-28-2009
20100226954POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.09-09-2010
20110117159INHIBITION OF JAK2 AS A TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - The present invention relates to a method of treating pulmonary arterial hypertension by administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof.05-19-2011
20100255050Polyethylene Based Bioactive Agents - The present invention concerns an acyclic diene metathesis (ADMET) chemistry-based method of making polymers incorporating biologically active molecules, and the polymers formed thereby. Functionalized polymers prepared by this method can be used to produce a broad range of commercially important products such as drag delivery agents (prodrugs), chromatography reagents (e.g., for use in separatory reagents), biomimetics, and biodegradable synthetic polymers.10-07-2010
20090148486COMPOSITIONS AND METHODS FOR TREATING PULP INFLAMMATIONS CAUSED BY INFECTION OR TRAUMA - The present disclosed subject matter relates to methods and compositions for restoring a diseased or damaged tooth such that infection is inhibited or eliminated and pulp regeneration is facilitated. The disclosed subject matter also includes a composition comprising a physiologically acceptable matrix seeded with pulp cells. The matrix can be capable of being injected into the pulp chamber of a tooth. In some embodiments, the matrix of a composition includes a hydrogel (e.g., collagen, chitosan, alginate, MATRIGEL™, gelatin, JELL-O®, fibrin), a mesh (e.g., polylactide-coglycolide (PLGA) mesh, polylactide (PLA) mesh, or polyglycolide (PGA) mesh, a cross-linked fiber mesh, a nanofiber mesh, a mesh fabric, biodegradable polymer mesh), a microsphere (biodegradable polymer microsphere, a hydrogel microsphere), or a combination of any of the foregoing. In yet other embodiments, the matrix includes a nanofiber, an artificial three-dimensional scaffold material, or a synthetic three-dimensional scaffold material.06-11-2009
20090155330Vaccine Delivery via Microneedle Arrays - A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer.06-18-2009
20090297574FLEXABLE SPIRALLY-ROLLED POLYMER TUBE FOR MONITORING AND TREATMENT OF BRAIN INJURIES - A flexible spirally-rolled polymer microtube for in vivo monitoring and treatment of brain injuries; the tube integrally comprising one or more microsensors and one or more microchannels, wherein the microsensors monitor one or more parameters and the microchannels are capable of delivering substances to the brain, removing substances from the brain, or both.12-03-2009
20090186060METHODS OF ENHANCING RADIATION EFFECTS WITH METAL NANOPARTICLES - The present invention provides methods of using metal nanoparticles 0.5 to 400 nm in diameter to enhance the dose and effectiveness of x-rays or of other kinds of radiation in therapeutic regimes of ablating a target tissue, such as tumor. The metal nanoparticles can be administered intravenously, intra-arterially, or locally to achieve specific loading in and around the target tissue. The metal nanoparticles can also be linked to chemical and/or biochemical moieties which bind specifically to the target tissue. The enhanced radiation methods can also be applied to ablate unwanted tissues or cells ex vivo.07-23-2009
20080286321Polymer No Donor Predrug Nanofiber Coating for Medical Devices and Therapy - The present invention relates to nanofibers that produce therapeutic amounts of nitric oxide after a delay period, which allows time to install or implant the device into a patient. The nitric oxide release is thus localized to the area of the organism where NO dosing is indicated. The delay time is achieved by cospinning the NO-producing fiber with a fiber that tends to sequester the former's NO-producing functional groups. Fibers of the present invention may be incorporated into medical devices such as stents or other implantable medical devices to prevent the formation of adhesions or scarring in the area of the implant.11-20-2008
20120003291NANOBEAD RELEASING MEDICAL DEVICES - Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided.01-05-2012
20120015020BIODEGRADABLE DRUG OR OTHER ACTIVE DELIVERY SYSTEM - A nonwoven fabric has been developed as a delivery system for drugs or other actives which includes biodegradable and biocompatible fibers with plant virus nanoparticles. The plant virus nanoparticles are pre-loaded with one or more actives.01-19-2012
20120015019Drug Coated Balloon With In-Situ Formed Drug Containing Microspheres - The current invention relates to methods of forming a coating that involves the in-situ formation of drug microspheres. The coating may be applied to a medical device, such as a catheter balloon or a stent. Coated devices and methods of treatment therewith are also encompassed within the embodiments of the present invention.01-19-2012
20090136553TRIGGERABLY DISSOLVABLE HOLLOW FIBERS FOR CONTROLLED DELIVERY - Provided are tubular structures of a biocompatible, triggerably-dissolvable material such as cellulose or a copolymer having an LCST below physiological temperatures. The structures may be embedded within a cell growth scaffold. The tubular structures are useful in growing 3-dimensional tissue structures because nutrients, cytokines or other cell growth and/or differentiation compounds, as well as drugs, such as antibiotics and steroids, can be administered over time, and the tubular structures can be dissolved non-invasively.05-28-2009
20120058170DRUG DELIVERY BY CARBON NANOTUBE ARRAYS - The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays.03-08-2012
20080305139Pharmaceutical Compositions Comprising Dextran with a Molecular Weight of 1.0-100 Kda and Processes for Their Preparation - A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.12-11-2008
20100189758COATING CONTAINING PEGYLATED HYALURONIC ACID AND A PEGYLATED NON-HYALURONIC ACID POLYMER - Provided herein are a method, which comprises implanting in a patient an implantable device comprising a coating that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.07-29-2010
20120064141Drug-Coated Balloon With Location-Specific Plasma Treatment - Method of coating an expandable member, e.g. balloon, is provided, the method comprising providing an expandable member having an outer surface. The method includes a plasma treatment with a supply of gas performed on at least a portion of the outer surface of the expandable member. A therapeutic agent is applied on at least the plasma treated portion of the outer surface of the expandable member after the plasma treatment is performed. The plasma treatment can reduce the adhesion of therapeutic agent to the surface of the expandable member. A medical device made by the disclosed method is also provided.03-15-2012
20120156276Connective tissue stimulating peptides - Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG” and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “P” in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.06-21-2012
20110045047HEMOSTATIC IMPLANT - The present disclosure relates to collagen-containing implants including a porous substrate having a first hydrogel precursor and a second hydrogel precursor applied thereto in a manner such that the first hydrogel precursor and second hydrogel precursor do not react with each other until the implant is placed at the site of implantation and exposed to the physiological fluids of a patient.02-24-2011
20090022768Continuous flow chamber device for separation, concentration, and/or purification of cells - The present invention relates to methods and apparatuses for neutralizing cancer cells. In particular, the invention relates to separating of cancer cell type from a mixture of different cell types based on the differential rolling property of cancer cell on a substrate coated with a first molecules that exhibits adhesive property with the particular cell type and neutralizing the cancer cell by a second molecule that is also coated on the substrate. This technology is adaptable for use in vivo, in vitro, or ex vivo tumor neutralization.01-22-2009
20110091516Muscle-based grafts/implants - The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic gent to attract a desired cell.04-21-2011
20100291172Sterile Autologous, Allogenic or Xenogenic Implant and the Method of its Production - The subject of the invention is a sterile, dehydrated acellular implant, which during its rehydration by water or bodily fluids displays anisotropic expansion and can act as a substrate for adhesion, migration and growth of live cells. Collagen structures of the transplant are at least partially denatured through the action of heat or organic solvents, such as lower aliphatic alcohols and ketones, which simultaneously act as preservative and sterilization agents, especially for certain types of viruses. The implant is sterilized by radiation while in an substantially dehydrated state, preferably by accelerated electrons. The transplant can be derived from various animal tissues, especially mammalian tissues, such as human or porcine tissues. The tissues suitable for the invention can be, for example, skin, placenta, pericardium, peritoneum, intestinal wall, tendon, blood vessel, etc. The implant is suitable for use in human and veterinary medicine, for instance as a temporary wound and burn cover, for the repair, substitution and regeneration of tissues, and also as a substrate for laboratory cell cultivation.11-18-2010
20100291171HYALURONIC ACID DERIVATIVES OBTAINED VIA "CLICK CHEMISTRY" CROSSLINKING - Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules.11-18-2010
20110104226PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN A1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR - A peptide having an ED05-05-2011
20110104225POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR - A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.05-05-2011
20100092532Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases - Disclosed herein are materials and methods suitable for treating sites of pathological angiogenesis and abnormal neovascularization. Sites of pathological angiogenesis or abnormal neovascularization can be treated by contacting a surface at or adjacent or in the vicinity of an area of pathological angiogenesis or abnormal neovascularization with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected site. The composition can be a flexible planar material or a flowable composition. Diseases susceptible to treatment with the present invention include, for example, macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic inflammatory diseases, and treatment of tumors by surgical resection, radiation therapy or chemotherapy.04-15-2010
20100092533Bioabsorbable Surgical Composition - Bioabsorbable macromer compositions are provided including a polymeric component possessing a hydroxamate segment and a polymer segment. The polymeric component can be used by itself, or in some embodiments, combined with a second component, to form a macromer composition of the present disclosure. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.04-15-2010
20100247593NOVEL COMPOUNDS AND PHARMACEUTICAL PREPARATIONS - Ectracts and pharmaceuticals form 09-30-2010
20100247594DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.09-30-2010
20100247595POROUS STRUCTURES AND METHODS OF USE - The present invention provides porous structures that each comprise chitosan, alginate and divalent metal cations, wherein: (a) the chitosan is ionically linked to the alginate; and (b) the structure is porous and has a compressive yield strength of at least 0.35 MPa. The present invention also provides methods for making the porous structures, and methods for using the porous structures as substrates to grow living cells.09-30-2010
20090098174HEPARIN COATING OF BIOLOGICAL TISSUE - The present invention discloses an in vitro method to provide biological tissue with a heparin coating comprising the following steps; linking a biotin reagent to biological tissue, linking an avidin reagent to the biotinylated biological tissue, and linking a heparin reagent to the formed layer of avidin on the biological tissue thus forming a heparin coating. The invention further discloses a heparin coating on biological tissue, the use of a heparin coating, and the biological tissue coated with a heparin layer according to the method.04-16-2009
20120135061PARY-XYLENE BASED MICROFILM ELUTION DEVICES - This invention is in the field of controlled elution devices for therapeutic delivery. There exists a need for a stand-alone capable device for the localized and extended delivery of a therapeutic. This need is overcome by the present invention having an exemplary embodiment comprised of a microfilm base (05-31-2012
20100172950PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTRAN WITH A MOLECULAR WEIGHT OF 1.0-100 KDA AND PROCESSES FOR THEIR PREPARATION - A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.07-08-2010
20100172949CONSENSUS PEPTIDE - The present invention relates to artificial peptides optimized for the induction and/or stimulation of mineralization and/or biomineralization. The invention also relates to the use of these artificial peptides for the induction and/or stimulation of mineralization and/or biomineralization in vivo and in vitro.07-08-2010
20100047306PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES - The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers. The depot formulation may be in the form of microparticles or implants. The depot formulations are useful for the treatment and prevention of proliferative diseases including cancer.02-25-2010
20100047305Extracellular Matrix Compositions - The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.02-25-2010
20120177715HEPARIN COFACTOR II FRAGMENTS WITH ANTI-INFLAMMATORY AND ANTI-COAGULANT ACTIVITY - The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOS: 1 to 3, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.07-12-2012
20100272775IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY FOLLOWING STERILIZATION - The present invention relates to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.10-28-2010
20100272774DEVICES AND METHODS FOR DELIVERY OF BIOACTIVE AGENTS - Embodiments of the invention include bioactive agent eluting devices. In an embodiment the invention includes a bioactive agent delivery device including a substrate, a hydrophilic polymer disposed on the substrate, and a substantially amorphous bioactive agent disposed on the surface of the hydrophilic polymer. In an embodiment, the invention includes a method of making a bioactive agent delivery device including depositing a hydrophilic polymer on a substrate forming a hydrophilic surface and depositing a substantially amorphous bioactive agent on the hydrophilic surface. In an embodiment, the invention includes a bioactive agent-eluting catheter including a catheter shaft and an expandable balloon disposed on the catheter shaft. Other embodiments are included herein.10-28-2010
20100272773Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device - When making a medical device having a drug coating thereon, the drug having a plurality of characteristic morphological forms, the manufacturing process is controlled to produce a predetermined ratio of said morphological forms on the device. The process has application to drug coated balloons.10-28-2010
20100008965BIOCOMPATIBLE MEDICAL PRODUCTS HAVING ENHANCED ANTI-THROMBOGENIC PROPERTIES - Described are medical products including a plurality of polypeptides having an amino acid sequence derived from fibronectin, and particularly those polypeptides having an amino acid sequence derived from the type III connecting segment domain of human fibronectin. Such polypeptides have a higher affinity for binding endothelial cells as compared to platelets; thus resulting in a medical product having enhanced anti-thrombogenic properties. As such, medical products as described herein find particular use in vascular applications, and particularly to repair or replace vascular vessels prone to acute thrombosis. Related methods of manufacture and use are also described.01-14-2010
20090060969Porous biodegradable polymeric materials for cell transplantation - Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.03-05-2009
20090060968INHIBITORS OF PHOSPHATASES - The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases.03-05-2009
20120258159MALLEABLE, BIODEGRADABLE HEMOSTATIC AGENT - A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water.10-11-2012
20090035343DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.02-05-2009
20110123591TUMORICIDAL, BACTERICIDAL, OR VIRICIDAL MACROPHAGE ACTIVATION - The activation of macrophages and methods for treating cancer, bacterial pathogens and viral pathogens are disclosed. In particular, Gc protein is converted to Gc-macrophage activating factor (GcMAF), in vivo or ex vivo. The GcMAF activates macrophages which can then target cancer cells, bacterial pathogens and/or viral pathogens. Alternatively, macrophages are activated by contacting them, in vivo or ex vivo, with GcMAF. Optionally, nagalase is inactivated in a patient receiving the present macrophage activating treatment by contacting the patient's blood with a Nagalase-binding ligand immobilized on an inert medium.05-26-2011
20080299165Compositions for Treatment of Diseases of the Nail Unit - A flowable composition suitable for use as a controlled release implant, the composition comprising a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid; a biocompatible polar aprotic solvent selected from the group consisting of an amide, an ester, a carbonate, a ketone, an ether, and a sulfonyl; wherein the biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid, and antifungal active.12-04-2008
20080299166NOVEL BIOMATERIALS, THEIR PREPARATION AND USE - The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 12-04-2008
20080299164Substituted polycaprolactone for coating - A coating formed of a substituted polycaprolactone and method of making and using the same are disclosed.12-04-2008
20110002972NEUROENDOCRINE FACTORS FOR TREATMENT OF DEGENERATIVE DISEASES - The present invention is related to the use of a repellent factor and/or polypeptide for manufacturing of a pharmaceutical composition for treating a disease such as a degenerative disease in particular to the use of a SLIT3 or NETRIN1 protein therefore. The invention is further related to a polypeptide fragment of SLIT3, a pharmaceutical composition comprising the polypeptide and the use thereof.01-06-2011
20100233229IN-VIVO INDWELLING DEVICE - An in-vivo indwelling device suitable for placement indwelling in a lumen in vivo, including an in-vivo indwelling device main body, and a layer containing a medium-chain fatty acid triglyceride formed on at least a part of a surface of the in-vivo indwelling device main body.09-16-2010
20100233228Drug-Eluting Medical Device - A drug-eluting medical device includes a catheter balloon completely or partially coated with paclitaxel in anhydrous crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the intervention site. The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12.09-16-2010
20090274737IMPLANT COMPRISING A SURFACE OF REDUCED THROMBOGENICITY - An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of Θ, where Θ≦80°. Also disclosed is a method for producing an implant and the use an implant to reduce the dose or concentration in administration of a concomitant systemic medication with one or more anticoagulant active ingredients before, during or after implantation of the implant in a human or animal body.11-05-2009
20110223231FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.09-15-2011
20110236454INJECTABLE DRUG DELIVERY FORMULATION - The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the formulation is substantially free of water. The invention also provides a drug delivery depot formed from the injectable formulation wherein the polymers crosslink in the presence of water in the body of a patient, or in the air, prior to implantation in the patient. Also provided are methods of treatment using such formulations and drug delivery systems.09-29-2011
20100233227MEDICAL DEVICES HAVING CARBON DRUG RELEASING LAYERS - According to various aspects of the invention, medical devices are provided, which comprise (a) a substrate, (b) a drug-containing layer disposed over the substrate, which contains one or more drugs and, optionally, one or more additional materials, and (c) a carbon layer disposed over the drug-containing layer.09-16-2010
20100233226DRUG-ELUTING NANOWIRE ARRAY - The present invention relates to a nanowire array (09-16-2010
20100233225Method of surface coating devices to incorporate bioactive molecules - A first embodiment is a coating for a surface comprising an electrostatic self-assembly creating one or more coating layer(s); (i) wherein one or more high molecular weight bioactive molecule(s) is bound to a protein carrier wherein said protein carrier or said bound bioactive molecule is further bound to one or more of said coating layer(s) and/or (ii) wherein one or more low molecular weight bioactive molecule(s) is/are incorporated within one or more of said layers or later introduced to said layer or layers by post-treatment. A second embodiment is a method of coating a surface comprising introducing said surface into a solution of one or more positively charged water-soluble polyelectrolytes at a pH ranging from about 2 to about 12 and at a temperature ranging from about 4° C. to about 80° C. and incubating said surface for about 0.5 to about 60 minutes; Rinsing said surface with said buffer solution or water to remove weakly bound material on said surface and dry by means known to one skilled in the art; Introducing said surface into a solution of one or more negatively charged water-soluble polyelectrolytes at a pH ranging from about 2 to about 12 and at a temperature ranging from about 4° C. to about 80° C. and incubating said surface for about 0.5 to about 60 minutes; and Rinsing said surface with said buffer solution or water to remove weakly bound material on said surface and passively or actively drying said surface.09-16-2010
20110244014IMPLANTABLE MEDICAL ARTICLES HAVING LAMININ COATINGS AND METHODS OF USE - Laminin-containing coatings for the surfaces of implantable medical devices are disclosed. The coatings promote the formation of vessels in association with the coated surfaces with minimal fibrotic response.10-06-2011
20100215709MEDICAL DEVICE WITH INFLAMMATORY RESPONSE-REDUCING COATING - Implantable non-bioabsorbable medical devices have an amphiphilic coating for reducing the inflammatory response to the device after implantation.08-26-2010
20120100199METHOD FOR TREATING A PERIODONTAL DISEASE - Provided is a method for treating a periodontal disease affecting a periodontal pocket of a patient. The method includes inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, including a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent.04-26-2012
20110159068Osteogenic composition comprising a growth factor/amphiphilic polymer complex, a soluble cation salt and an organic support - An open implant constituted of an osteogenic composition comprising at least one osteogenic growth factor/amphiphilic anionic polysaccharide complex, one soluble salt of a cation at least divalent, and one organic support, said organic support comprising no demineralized bone matrix. In one embodiment, said implant is in the form of a lyophilizate. It also relates to the method for the preparation thereof.06-30-2011
20110159067HYDROPHOBIC POLYSACCHARIDES WITH PENDENT GROUPS HAVING TERMINAL REACTIVE FUNCTIONALITIES AND MEDICAL USES THEREOF - Hydrophobic α(1→4)glucopyranose polymers useful for the preparation of implantable or injectable medical articles are described. The hydrophobic α(1→4)glucopyranose polymer includes pendent groups having hydrocarbon groups and terminal amine or hydroxyl groups. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo. Matrices including and capable of releasing a bioactive agent in vivo are also described.06-30-2011
20110159066Methods For Treating Parkinson's Disease - Methods for restoring normal patterns of activity in a subject suffering from Parkinson's Disease are disclosed that include administering an effective steady state concentration of a dopamine modulating compound continuously for a prolonged period of time such that normal patterns of activity are substantially restored in the subject.06-30-2011
20080254089PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES - A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.10-16-2008
20080254088SHAPED BODIES BASED ON A CROSS-LINKED, GELATINOUS MATERIAL, METHOD FOR PRODUCING SUCH BODIES AND USE OF THE BODIES - Shaped bodies based on gelatin which have both high mechanical strength and also sufficient flexibility are provided, the shaped body comprising a cross-linked, gelatinous material which comprises gelatin and a plasticizer, the shaped body being stretched so that the gelatin molecules are oriented at least in part in a preferred direction.10-16-2008
20080254086Controlled Release Compositions - Controlled release compositions for controlling release of a GnRH molecule or a GnRH analog are provided. The compositions include a GnRH molecule or GnRH analog as an active agent, and a controlled release component for controlling release of the GnRH molecule or GnRH analog from the composition. The compositions provide a sustained mean steady state plasma concentration (C10-16-2008
20080254085Degradable Polymers Incorporating Gamma-Butyrolactone - Disclosed herein are implantable medical devices having controlled release biodegradable polymer coatings thereon wherein the polymer is formed from ring opening of γ-butyrolactone and at least one additional monomer selected from the group consisting of trimethylene carbonate, lactide, polyethylene glycol, glycolide, the monomers formed from ring opening of ε-caprolactone, 4-tert-butyl caprolactone, and N-acetyl caprolactone, and combinations thereof, and at least one drug releasable from the biodegradable polymer. Also disclosed are implantable medical devices form of the biodegradable polymers and processes for forming the polymers.10-16-2008
20090117167Injectable capsaicin with vasocontrictor adjunctive agent - Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasoconstrictor.05-07-2009
20090258046COMPOSITION, FORMULATIONS AND KIT FOR TREATMENT OF RESPIRATORY AND LUNG DISEASE WITH NON-GLUCOCORTICOID STEROIDS AND/OR UBIQUINONE AND A BRONCHODILATING AGENT - A pharmaceutical or veterinary composition, which comprises a first active agent selected from a non-glucocorticoid steroid or analogues, a ubiquinone, or salts thereof, and a second active agent comprising a bronchodilator. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of respiratory, lung and malignant diseases.10-15-2009
20080233163Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof - Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, pharmaceutical compositions and medical devices containing such compounds and methods utilizing such compounds in the treatment of various medical conditions.09-25-2008
20090208549Devices and Methods for Reverse Lipid Transport - The present disclosure relates to devices methods for the reverse transport of lipids such as cholesterols for the treatment diseases and conditions caused by vulnerable plaques. The devices can reduce or eliminate vulnerable plaques by transporting the plaques away from their location.08-20-2009
20080226687Drug delivery and method having coated microprojections incorporating vasoconstrictors - A device and method are provided for percutaneous transdermal delivery of a biologically active agent. The coating formulation containing the biologically active agent and a vasoconstrictor is applied to the skin piercing elements using known coating techniques and then dried. The device is applied to the skin of a living animal, causing the microprojections to pierce the stratum corneum and to deliver an effective dose of the biologically active agent and vasoconstrictor to the animal.09-18-2008
20080226686GENERATION OF NITRIC OXIDE IN SITU AT SUBSTRATE/BLOOD INTERFACES AND REPRODUCIBLE NITRIC OXIDE SENSOR FOR DETECTING NITROSOTHIOLS - A material includes a surface and a reactive agent that is located at the surface of the material, covalently attached to a backbone of the material, and/or located within the material. The reactive agent has nitrite reductase activity, nitrate reductase activity, and/or nitrosothiol reductase activity. The reactive agent also converts at least one of nitrites, nitrates and nitrosothiols to nitric oxide when in contact with blood. A reproducible nitrosothiol sensor is also disclosed.09-18-2008
20110212152MODIFIED ANTI-MICROBIAL SURFACES, DEVICES AND METHODS - Methods for making modified surfaces and in particular, surfaces that may be lubricious and may be further treated to be anti-microbial are disclosed. Devices comprising modified surfaces prepared by the methods are also disclosed. An exemplary method comprises incubating a photo-initiator-coated substrate in an aqueous monomer solution that is capable of free radical polymerization, exposing the incubating substrate to ultraviolet (UV) light creating a modified surface on the substrate. An anti-microbial agent may be added to the modified surface.09-01-2011
20080199503Pharmaceutical Compositions Preparation of Peptides, Secreted by the Snake Venom Glands, Particularly of Bothrops Jararaca, Vasopeptidases Inhibitors, Evasins, Their Analogues, Derivatives and Products Associated, Thereof, for Development of Applications and Use in Chronic-Degenerative Diseases - The present invention is characterized by the process of preparation of pharmaceutical compositions for the development of applications of the Evasins and their structural and/or conformational analogues in chronic-degenerative diseases. It is further characterized by the process of preparation of pharmaceutical compositions and related products of the Evasins peptides and their structural and/or conformational analogues in using the cyclodextrins, its derivatives, liposomes and biodegradable polymers and/or mixture of these systems. The invention is further characterized by the increased efficacy of these peptides and their analogues included in cyclodextrins, when administered to rats. This characterizes an increased biodisponibility of these peptides and their analogues using the compositions of the present invention.08-21-2008
20100285083DRUG DELIVERY SYSTEM - It is a main object of the present invention to provide a drug delivery system in which drugs can be changed or which can be recharged with drugs, which continuously delivers drugs at effective concentrations to local lesional sites in a body and allows the use of drugs for which it has thus far been difficult to achieve effective local concentrations for a variety of reasons and drugs which have been difficult to use due to adverse effects on tissues that are not sites of action. The present invention provides a drug delivery system comprising an indwelling medical device on which a biocompatible material having target molecules on its surface has been coated, and target-recognizing nanocarriers (e.g., bio-nanocapsules, liposomes, liposome preparations, and nanoparticles) in which drugs are encapsulated and which have target-recognizing molecules capable of specifically binding to the target molecules.11-11-2010
20100316687HYDROPHOBIC POLYSACCHARIDES WITH DIESTER- OR CARBONATE ESTER-CONTAINING LINKAGES HAVING ENHANCED DEGRADATION - Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a chemistry that facilitates degradation of the polymer. Diester and carbonate ester linker chemistries are exemplified. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.12-16-2010
20100316686Osteosynthesis with nano-silver - The present invention relates generally to an antibacterial coating which is composed of silver, to medical tools and to implants comprising such a coating and to a method as well to an apparatus for the production of such a coating. The medical tools or the dental or orthopaedic implant comprises a metal or metal alloy having a treated surface wherein the treated surface is at least partially converted to an oxide film by plasma electrolytic oxidation using a colloid-dispersed system and wherein the converted surface is partially covered by islands formed by colloid-dispersed silver-particles of the colloid-dispersed system. An Ag—TiO12-16-2010
20120003290METHOD FOR REDUCING PAIN - The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.01-05-2012
20120021038COATING COMPOSITION - A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours.01-26-2012
20120021037MEDICAL DEVICES WITH AN ACTIVATED COATING - Implantable medical devices include a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity.01-26-2012
20120021036COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM - The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications.01-26-2012
20120021035Nanoparticles containing plymeric nucleic acid homologs, pharmaceutical composition and articles of manufacture containing same and methods of use thereof - A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.01-26-2012
20120027833DRUG-ELUTING FILMS - Polymeric porous films, capable of eluding a bioactive agent when coming in contact with a physiological medium according to a pre-determined and controlled release profile suitable for particular type of drug and indication, and medical devices including the same are disclosed. Also disclosed are processes for producing the polymeric porous films by freeze-drying an inverted emulsion formulation in which the polymer's composition, the polymer's concentration, the polymer's initial molecular weight, the concentration and/or the type of a surfactant, the homogenization rate and/or the oil phase to aqueous phase ratio (O:A) are selected so as to impart a desired release profile of the bioactive agent from the polymeric film.02-02-2012
20120039980COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE - Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.02-16-2012
20130202672FIBER-ASSEMBLED TISSUE CONSTRUCTS - The present invention relates to a fiber-assembled tissue construct comprising at least one sinusoid unit, the unit comprising at least two polymeric fibers arranged in a sinusoid structure and fused together, each of said fibers comprising a porous matrix supporting biological components encapsulated in the fiber, wherein the biological components are patterned in three-dimensions within the construct.08-08-2013

Patent applications in class Implant or insert

Patent applications in all subclasses Implant or insert